Gideon M. Blumenthal

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 473 citations · Full text

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

Joohee Sul, Gideon M. Blumenthal, Xiaoping Jiang et al. · The Oncologist · 2016 · 360 citations · Full text

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 336 citations

Metastatic Breast Cancer, Independent Review Committee, Breast Oncology +13

Real-world Data for Clinical Evidence Generation in Oncology

Sean Khozin, Gideon M. Blumenthal, Richard Pazdur · JNCI Journal of the National Cancer Institute · 2017 · 332 citations · Full text

Clinical Endpoint, Real-world Evidence, Cancer Registration +22

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Aviva C. Krauss, Xin Gao, Liang Li et al. · Clinical Cancer Research · 2018 · 315 citations · Full text